continu strong momentum pt
adjust given pullback
updat sales/gaap ep
 assum om
sale estimate consensu
report ep slightli consensu
adj vs abmd sale guidanc expect om rang
lower dcf base pt
recognit stock trade today slight adj discount
 termin growth overal sale
trajectori unchang maintain buy
updat fy estim updat fy sales/gaap
ep cc cc
 exhibit assum om
estim compar consensu gaap
mechan circulatori support tmc model extend
identifi non-overlap patient segment like larg
respons futur impella growth remain unchang previous
publish schemat project overal tmc unit grow approxim
exhibit project impella-lik unit
rise period compound-annual-growth-rate process
updat patient level tmc schemat incorpor inpati
actual model previous reli inpati data better
align project framework provid focus patient
sub-seg compel need mechan support
highli like support impella-lik devic
within identifi around cardiogen shock admiss
grow period
patient almost entir label given recent indic expans
encompass cardiogen shock link believ market
around penetr major tmc usag compris
isol balloon pump impella versu impella usag across
indic
continu pg
tr target
evid develop amongst patient suffer cardiogen shock underli
cardiomyopathi etiolog like help open anoth adjac non-overlap popul
patient acut systol heart failur acut kidney injuri impella seem renal protect
amongst under-perfus patient dont suffer cardiogen shock undergo pci
patient cohort total grow period link
almost usag tmc regard high risk pci w/o cardiogen shock identifi
admiss co-cod risk factor systol heart failur and/or acut kidney injuri
and/or prolong length stay rate acut kidney injuri amongst admiss
versu inpati receiv pci link total patient versu
high risk pci impella usag like somewhat overlap also addit high
risk pci total could around stemi patient anterior mi undergo pci circa
dont cardiogen shock link studi upcom dtu pivot
trial reduct absolut infarct size dtu rel seen without tmc could drive
standard care chang final appear larg multipl less well defin
high risk cohort acut coronari syndrom patient ami unstabl angina dont overlap
aforement cardiogen shock high risk pci acut systol heart failur group link
valuat risk price target dcf base predic explicit model
abmd fy termin year assum corpor revenu ex-u
oper margin assum discount rate termin growth factor
given high oper margin structur compani suffici cash readili avail
technolog acquisit princip risk thesi evid develop adjac
segment ami w/o cs pci acut systol heart failur without cs pci ami may
develop curtail market opportun addit competit encroach may come faster
harder envis final abmd strong valuat reflect long tail opportun
short term miss rel street expect could caus abrupt pull-back
page
page
strh estimatesabmdconsensusstrh vs consensu cc est us us impella revenu impella product statementstrh estimatesabmdconsensusstrh vs consensu cc adjust incl incom incom incom adj estimatesabmdconsensusstrh vs consensusmargin expens margin adjust incl inc
page
strh estimatesstrhconsensusstrh vs consensu cc est us us impella impella product statementstrh estimatesstrhconsensusstrh vs consensu cc adjust incl incom incom incom adj estimatesstrhconsensusstrh vs consensusmargin expens margin adjust incl inc
exhibit us tmc adopt assumpt segment
nation inpati sampl ni healthcar util project hcup agenc healthcar
research qualiti ahrq compani file strh estim
page
compound-annual-growth-rate shockisol w/o csisol w/o cs pciisol w/o cs pci amiisol indicationsisol tmcsisol shareisol asp patient inc
page
million except impella ou impella revenu total impella product servic total product fund total gross research total oper oper incom total incom expens pre-tax tax paid tax incom ep average share total reconciliations- net incom ep margin margin analysi yoy us impella impella impella revenu impella product impella product revenu revenu revenu oper incom incom abiom inc
 base danver
result proprietari databas analys believ impella-lik devic us
market opportun present larg opportun unlik
measur competit valuat also augment high intrins profit
impella revenu gross margin north rate share buy
valuat risk
price target dcf base predic explicit model abmd fy
termin year assum corpor revenu ex-u oper
margin assum discount rate termin growth factor given high oper
margin structur compani suffici cash readili avail technolog acquisit
princip risk thesi evid develop adjac segment ami w/o cs
pci acut systol heart failur without cs pci ami may develop curtail market
opportun addit competit encroach may come faster harder envis
final abmd strong valuat reflect long tail opportun short term miss rel
street expect could caus abrupt pull-back
compani mention note
bruce nudel herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
